Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Semaglutide Trends & Statistics

EMARKETER offers market research, trends and statistics for a variety of topics and industries. Here you will find a collection of reports, articles and other resources for Semaglutide
Novo Nordisk’s Super Bowl play spotlights weight loss pill credibility amid copycat drug confusion

Novo Nordisk’s Super Bowl play spotlights weight loss pill credibility amid copycat drug confusion

Article
Feb 06, 2026

Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.

GLP-1 drugs expected to drive 2026 pharma sales

Article
Jan 23, 2026

Lilly’s tirzepatide is projected to top 2026 sales as pills and uses beyond diabetes and weight loss expand demand.

Novo Nordisk letting its semaglutide patent expire in Canada is a major win for weight loss drug market players

Article
Jul 10, 2025

The news: Hims & Hers will soon expand its business to Canada, where it plans to sell generic semaglutide. The bottom line: Novo just gave a massive gift to healthcare companies that are in the weight loss drug market but can no longer sell compounded GLP-1s now that the brand-name versions are available again. We’ll likely see more players in this space that primarily operate in the US expanding north of the border, while others could take advantage of President Trump’s executive order that calls for the FDA to authorize more states to import lower-cost drugs from Canada.

Novo Nordisk missed a patent deadline in Canada, opening the door to generic GLP-1s as soon as 2026

Article
Jun 17, 2025

The news: Novo Nordisk missed an important patent filing deadline in Canada for its weight loss and diabetes drug semaglutide, opening the door to generics as soon as next year. Our take: If Sandoz and other generic makers start selling semaglutide GLP-1 drugs in Canada next year, FDA approval for states may not matter. If drugmakers do start selling generic GLP-1s in Canada, Novo will see Ozempic brand sales drop, but the GLP-1 market could see a generics’ explosion.

Hims & Hers isn’t giving up the compounded weight loss drug battle

Hims & Hers isn’t giving up the compounded weight loss drug battle

Article
Feb 25, 2025

Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.

FDA’s compounded GLP-1 limits will have ripple effects throughout the retail industry

FDA’s compounded GLP-1 limits will have ripple effects throughout the retail industry

Article
Jan 22, 2025

It’s about to get a lot harder to get cheap GLP-1s: Rising costs may force consumers to cut back on discretionary spending, creating headwinds for retailers already fearing tariff-driven cost increases.

Drugmaker asks FDA to ban compounding pharmacies from making Ozempic’s key ingredient

Drugmaker asks FDA to ban compounding pharmacies from making Ozempic’s key ingredient

Article
Oct 24, 2024

Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.

Eli Lilly’s GLP-1 medication shortage is over

Eli Lilly’s GLP-1 medication shortage is over

Article
Oct 03, 2024

Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.

Learn More About EMARKETER Market Research Tools and Insights.
Our premium research gives you need to unlock digital opportunities and make the right business decisions.
Learn how

Powerful data and analysis on nearly every digital topic.

Become a Client

Want more marketing insights?

Sign up for EMARKETER Daily, our free newsletter.

By clicking "Sign Up", you agree to receive emails from EMARKETER (e.g. FYIs, partner content, webinars, and other offers) and accept our Terms of Service and Privacy Policy. You can opt-out at any time.

Thanks for signing up for our newsletter!

You can read recent articles from EMARKETER here.
Already have a subscription?Sign In
Access All Charts and Data
  • Learn about what technologies are transforming your industry
  • Gain exclusive perspectives from top industry leaders
  • Access thousands of data sets and forecasts via our iconic charts
Become a Client
or